Gene therapy
Gene therapy is a therapeutic approach that delivers, replaces, regulates, or otherwise modifies genetic information to treat disease.
Gene therapy is a therapeutic approach that delivers, replaces, regulates, or otherwise modifies genetic information to treat disease. Depending on the disease and delivery system, the intended effect may be restoration of a missing protein, correction or compensation for a pathogenic genetic defect, modulation of cellular activity, or introduction of a therapeutic gene. The recent literature represented here includes adeno-associated virus (AAV) and other viral vectors, plasmid DNA, messenger RNA, small interfering RNA, CRISPR-Cas methods, lipid nanoparticles, and biodegradable nanocarriers as relevant genetic-medicine platforms.
Its biomedical significance spans inherited, neurological, hematological, hepatic, ocular, and malignant diseases. Examples include endogenous production of clotting factors in hemophilia, restoration of hepatocyte expression of the bile salt export pump (BSEP) in progressive familial intrahepatic cholestasis type 2, modulation of inhibitory neurons in epilepsy, and targeted treatment strategies for sickle-cell disease, GM2 gangliosidoses, and triple-negative breast cancer. The publications summarized below collectively extend translational applications across rare-disease models, tissue-specific delivery, cancer combinations, therapeutic regulation, and health-economic evaluation.
- Intravenous gene therapy improves life span and clinical outcomes in a feline model of Sandhoff disease. PMID 42715347
Where the papers sit
9 papers study gene therapy directly. Those 9 do not group into themes. Rare-disease treatment, cancer therapy, neurological targeting, delivery systems, regulation, and cost-effectiveness appear together without a shared biological question or convergent direction. They are no more alike than papers drawn from anywhere in the corpus. 1 paradigm shift follows.
Gene therapy is independently repurposed as a direct anticancer intervention rather than primarily as replacement of an inherited defect
The CD276-targeted antibody-drug conjugate plus mitochondrial cmLumiOpto study in triple-negative breast cancer and the intratumoral PD-1-overexpression study in triple-negative breast cancer (PMIDs 42497865, 42161051) depart from the inherited-disease replacement model exemplified elsewhere in the set. Instead of restoring a missing or defective protein, the first uses gene therapy to disrupt tumor mitochondrial function and enhance ADC activity, while the second uses it to inhibit tumor growth and stimulate antitumor immunity, with probiotic treatment mitigating intestinal toxicity. Together, these findings make gene therapy a means of reprogramming tumor and host biology within combination cancer treatment, not only a correction for inherited molecular deficiency.
Recent Findings on gene therapy
Sandhoff disease: An intravenous, bicistronic AAV vector-based gene therapy was evaluated in a feline model of Sandhoff disease. The study treated animals presymptomatically at one month of age and reported improved life span and clinical outcomes; the vector had not yet been tested in clinical trials 42715347Sep. This work places AAV-mediated gene delivery within a preclinical strategy for GM2 gangliosidoses and related lysosomal disease.
Ocular delivery: Researchers constructed and evaluated a biodegradable CS-PLGA/pEGFP/HA ternary nanocarrier for intravitreal gene delivery. The system incorporated plasmid DNA encoding enhanced green fluorescent protein (pEGFP) and was investigated as a potential candidate for intraocular gene therapy rather than as an established clinical treatment 42702980Sep. The study addresses local delivery of nucleic acids using a nonviral biodegradable carrier.
Epilepsy: A compact GAD67 promoter was developed for AAV gene therapy directed toward inhibitory neurons. The therapeutic rationale was to enhance inhibitory-neuron activity, restore excitatory–inhibitory balance, and suppress seizures, potentially offering an approach for treatment-resistant epilepsy 42349402Jun.
Triple-negative breast cancer and combination therapy: One study evaluated the combination of a CD276 (B7-H3)-targeted antibody–drug conjugate with cmLumiOpto, described as a mitochondria-targeted gene therapy 42497865Jul. The work therefore investigated gene therapy as part of a multimodal anticancer regimen rather than as a standalone intervention, with mitochondrial function included among the therapeutic targets.
Intratumoral PD-1 gene therapy: In a triple-negative breast cancer model, intratumoral PD-1 gene therapy was studied alongside modulation of the gut microbiota and tyrosine metabolism by Lactobacillus rhamnosus. The reported results characterized PD-1 gene therapy as having a dual effect within the experimental treatment strategy and examined its relationship to PD-1-mediated antitumor immunity 42161051May.
Sickle-cell disease: A cost-effectiveness analysis compared haploidentical transplantation, gene therapy, and standard care for sickle-cell disease. The study described gene therapy as another treatment capable of lifelong disease amelioration, while emphasizing that access is constrained by cost and manufacturing capacity in the United States and globally 42227898Jun. This work highlights implementation and health-system considerations in addition to biological efficacy.
Progressive familial intrahepatic cholestasis type 2: A liver-directed gene therapy was investigated in mice to ameliorate progressive familial intrahepatic cholestasis type 2. The approach was designed to restore BSEP expression in hepatocytes, directly addressing the disease-associated loss of this hepatic function 42579774Aug.
Hemophilia: A review of gene therapy for hemophilia described the field as a transformative strategy based on correcting genetic mutations and enabling endogenous production of clotting factors 41863244Mar. The article surveyed innovations, milestones, and future prospects rather than reporting a single experimental treatment.
Biomedical regulation: A policy analysis of China’s evolving biomedical-technology regulation addressed regulatory gaps affecting cell and gene therapies, as well as germline interventions 42349422Jun. This context underscores that gene therapy development involves governance and regulatory frameworks in addition to vector design, delivery, and clinical evaluation.
Together, these publications extend the translational theme represented across the entity’s literature: they do not converge on one shared biological mechanism, but instead cover rare-disease treatment, tissue-specific delivery, neuronal targeting, cancer combinations, hepatic repair, clinical access, and regulation.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Drafted by language models from published abstracts; not medical advice.